For the quarter ending 2025-12-31, CTXR made $3,944,111 in revenue. -$8,220,785 in net income. Net profit margin of -208.43%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | 3,944,111 | - | 0 | - |
| Cost of revenues | 789,208 | - | - | - |
| Gross profit | 3,154,903 | - | - | - |
| Research and development | 1,599,719 | 1,641,586 | 1,621,325 | 3,766,525 |
| Amortization of in-process research and development | 573,438 | - | - | - |
| General and administrative | 5,720,727 | 3,905,961 | 4,447,008 | 4,792,122 |
| Stock-based compensation general and administrative | 4,280,227 | 2,889,762 | 2,719,674 | 2,702,031 |
| Total operating expenses | 12,174,111 | 8,437,309 | 8,788,007 | 11,260,678 |
| Operating loss | -9,019,208 | -8,437,309 | -8,788,007 | -11,260,678 |
| Interest income | 45,097 | 53,423 | 20,637 | 13,413 |
| Interest expense | 155,538 | 95,520 | 172,262 | - |
| Gain on sale of new jersey net operating losses | - | - | 0 | - |
| Total other income (expense) | -110,441 | -42,097 | -151,625 | 13,413 |
| Loss before income taxes | -9,129,649 | -8,479,406 | -8,939,632 | -11,247,265 |
| Income tax expense | 264,240 | 264,240 | 264,240 | 264,240 |
| Net loss | -9,393,889 | -8,743,646 | -9,203,872 | -11,511,505 |
| Net loss attributable to non-controlling interest | -1,173,104 | -784,358 | -414,000 | -595,000 |
| Deemed dividend on warrant extension | - | - | 0 | - |
| Net loss applicable to common stockholders | -8,220,785 | -7,959,288 | -8,789,872 | -10,916,505 |
| Basic EPS | -0.38 | -0.463 | -0.8 | -1.27 |
| Diluted EPS | -0.38 | -0.463 | -0.8 | -1.27 |
| Basic Average Shares | 21,495,274 | 17,180,337 | 11,006,896 | 8,581,207 |
| Diluted Average Shares | 21,495,274 | 17,180,337 | 11,006,896 | 8,581,207 |
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)